Bio-Rad Laboratories, Inc.
BIOB
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -0.09% | 1.14% | 3.85% | 0.51% | 2.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.09% | 1.14% | 3.85% | 0.51% | 2.05% |
| Cost of Revenue | -0.36% | 1.18% | 11.49% | 5.80% | 8.31% |
| Gross Profit | 0.14% | 1.11% | -2.87% | -3.84% | -2.92% |
| SG&A Expenses | 2.02% | 1.68% | 6.26% | 2.36% | 6.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.66% | -0.68% | 5.90% | 0.22% | 6.77% |
| Operating Income | -5.70% | 43.93% | -13.38% | 3.03% | -23.18% |
| Income Before Tax | 30.94% | -927.10% | 202.23% | -150.03% | 114.86% |
| Income Tax Expenses | 77.44% | -938.66% | 208.34% | -142.80% | 115.50% |
| Earnings from Continuing Operations | 16.87% | -923.59% | 200.59% | -152.34% | 114.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.87% | -923.59% | 200.59% | -152.34% | 114.68% |
| EBIT | -5.70% | 43.93% | -13.38% | 3.03% | -23.18% |
| EBITDA | -3.31% | 21.45% | -5.63% | 6.96% | -13.95% |
| EPS Basic | 18.96% | -953.64% | 204.39% | -154.34% | 115.31% |
| Normalized Basic EPS | 8.39% | -6.89% | 9.96% | 9.30% | -23.86% |
| EPS Diluted | 18.68% | -953.83% | 204.23% | -154.41% | 115.30% |
| Normalized Diluted EPS | 8.13% | -6.85% | 9.82% | 9.44% | -23.87% |
| Average Basic Shares Outstanding | -1.76% | -3.52% | -3.65% | -3.67% | -4.12% |
| Average Diluted Shares Outstanding | -1.52% | -3.57% | -3.52% | -3.79% | -4.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |